Descrizione Clinica
Bench drugs Vitango 30cpr riv 200mg Loacker Remedia
VITANGO 200MG
active ingredients
A movie-coated tablet contains: Active ingredient: 200 mg of extract (as dry extract) of Rhodiola rosea L., rhizoma et radix (Rodiola rizoma and root) (1.5 - 5: 1) (WS 1375). Extraction solvent: ethanol 67.7% (v/v). For the full list of excipients, see paragraph 6.1.Excellent
Microcrystalline cellulose, sodium chrostatic, precipitated silica, magnesium stearate, ipromellose, stearic acid, iron oxide red E172, titanium dioxide E171, antifoam emulsion.Therapeutic indications
Traditional vegetable medicine indicated for the temporary relief of symptoms associated with stress, such as fatigue, exhaustion and mild anxiety states. The use of this traditional medicinal product of vegetable origin, for the therapeutic indications indicated, is based exclusively on the experience of multiannual use.Contraindications
Hypersensitivity to the active ingredient or any of the excipients listed in paragraph 6.1 Renal or liver failure.Population
Population. Adults: The recommended dose is 2 tablets daily. The maximum duration of treatment is 14 days. If symptoms persist contact your doctor. Pediatric population: The safety and effectiveness of VITANGO in children and adolescents under the age of 18 have not yet been established (see paragraph 4.4). Method of administration: VITANGO must be taken with a glass of water, preferably 30 minutes before taking food.Conservation
This medicine does not require any special condition of conservation.Warnings
Patients suffering from mood disorders must be treated properly. Use in children and adolescents under 18 years of age is not recommended.Interactions
Avoid the concomitant use of other products containing alcohol or acting on the central nervous system. Rhodiola rosea extracts are potential inhibitors of the CYP450 enzyme, drug interactions may occur.Effects
They were reported: reactions of hypersensitivity and hypoglycemia. Reporting of suspicious adverse reactions. The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address www.aifa.gov.it/content/segnalazioni-reazioni-avverse.Overdosing
No overdose cases have been reported.Safety during pregnancy and nursing with breast milk has not been established. The administration of VITANGO during pregnancy and nursing with breast milk is not recommended.
Source: Farmadati
